The 6 Best-Performing ETFs Over the Past Month

Joel Anderson |

So November is behind us and retail season is upon us. And while Movember may mean one thing to many people, certain ETFs treated it like the “mo” is short for “momentum.” As the year starts to wind down and major holidays start stacking on top of one another, it’s easy to start putting off any serious thought about your portfolio until the new year. However, the markets wait for no man (or woman). As such, here’s the six top-performing, non-leveraged ETFs of the last month:

1. SPDR S&P Pharmaceuticals ($XPH)

Index: S&P Pharmaceuticals Select Industry Index

Expense Ratio: 0.35 percent

Performance over last month: 11.85 percent

November proved a solid month for the nation’s biggest pharma companies. What’s more, it was a strong month for the health care industry as this is one of four ETFs in the sector to make the list.

2. iShares MSCI India Small-Cap Index Fund (SMIN)

Index: MSCI India Small-Cap Index

Expense Ratio: 0.74 percent

Performance over last month: 11.01 percent



This isn’t strictly a November gain as this includes an over 4 percent pop on Monday. But despite continuing concerns about the timing of the Fed’s taper, investors appear to be in a risk-on mode and willing to invest in volatile plays like emerging market small-cap companies.

3. SPDR S&P Biotech ETF ($XBI)

Index: S&P Biotechnology Select Industry Index

Expense Ratio: 0.35 percent

Performance over last month: 9.41 percent

With the second SPDR S&P health care ETF on this list, it’s clear that it was a good November not just for the sector, but for its biggest players.

4. PowerShares Dynamic Pharmaceuticals ($PJP)

Index: Dynamic Pharmaceuticals Intellidex Index

Expense Ratio: 0.60 percent

Performance over last month: 9.27 percent

The Pharmaceuticals Intellidex Index is comprised of 30 pharma companies and is designed to provide capital appreciation through evaluating companies based on investment merit critera that include price momentum, earnings momentum, quality, management action, and value.

5. iShares Nasdaq Biotechnology Index ETF ($IBB)

Index: Nasdaq Biotechnology Index

Expense Ratio: 0.48 percent

Performance over last month: 8.91 percent

Our final entry for the health care sector would seem to indicate that drug makers and biotech companies of all sizes were having a strong month in November.

6. iShares Dow Jones U.S Broker-Dealers ETF ($IAI)

Index: Dow Jones U.S. Select Investment Services Index

Expense Ratio: 0.48 percent

Performance over last month: 8.91 percent

Booming equities appear to have benefitted people selling equities in the process as this broker-dealer ETF gained almost 9 percent in November.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
BIOGY BioGaia AB (Sweden) ADR 11.02 0.00 0.00 0

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…